Fe-Mn-IGF-AMD nanoparticles in accurate detection and treatment of liver cirrhosis via regulating relaxation coefficients and attenuating hepatocyte senescence.

The working mechanism of anti-liver fibrosis medications is not fully understood, and we aimed to determine the effect of a novel nanotechnology-based delivery system by loading IGF-1 and AMD3100 onto Fe3O4 and MnO2 based drug carriers, forming Fe3O4-MnO2-IGF-1-AMD3100 nanoparticles (Fe-Mn-IGF-AMD NPs) on the treatment and detection of liver fibrosis. From an in vitro perspective, Fe-Mn-IGF-AMD NPs showed appropriate mechanical properties and good biocompatibility. In vivo, during the progression of liver cirrhosis, the Fe-Mn-IGF-AMD NP group exhibited favorable imaging capabilities and demonstrated significant anti-fibrotic effects, including inhibition of collagen deposition, suppression of hepatic stellate cell activation, attenuation of hepatocyte senescence, and reduction of reactive oxygen species, as confirmed by histological analysis, immunofluorescence staining, and western blotting. Accurate detection and satisfied treatment of liver cirrhosis were achieved in the Fe-Mn-IGF-AMD NP group.